Rafael Muniz

1.2k total citations
40 papers, 878 citations indexed

About

Rafael Muniz is a scholar working on Psychiatry and Mental health, Pediatrics, Perinatology and Child Health and Immunology. According to data from OpenAlex, Rafael Muniz has authored 40 papers receiving a total of 878 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Psychiatry and Mental health, 13 papers in Pediatrics, Perinatology and Child Health and 10 papers in Immunology. Recurrent topics in Rafael Muniz's work include Attention Deficit Hyperactivity Disorder (22 papers), Pharmaceutical studies and practices (13 papers) and Bipolar Disorder and Treatment (12 papers). Rafael Muniz is often cited by papers focused on Attention Deficit Hyperactivity Disorder (22 papers), Pharmaceutical studies and practices (13 papers) and Bipolar Disorder and Treatment (12 papers). Rafael Muniz collaborates with scholars based in United States, Japan and Switzerland. Rafael Muniz's co-authors include Linda Pestreich, Frank A. López, Hai Jiang, Thomas Spencer, Raul Silva, Matthew Brams, James J. McGough, Lenard A. Adler, C. Lindsay DeVane and John S. Markowitz and has published in prestigious journals such as Journal of Clinical Oncology, Biological Psychiatry and Journal of the American Academy of Child & Adolescent Psychiatry.

In The Last Decade

Rafael Muniz

35 papers receiving 814 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rafael Muniz United States	18	634	217	155	126	121	40	878
Nayan Acharya United States	15	238 0.4×	66 0.3×	56 0.4×	26 0.2×	232 1.9×	21	677
Richard Ammer Germany	13	316 0.5×	172 0.8×	22 0.1×	30 0.2×	28 0.2×	31	889
Nong Xiao China	14	152 0.2×	58 0.3×	158 1.0×	32 0.3×	46 0.4×	63	657
Debopam Samanta United States	18	574 0.9×	93 0.4×	327 2.1×	235 1.9×	15 0.1×	98	1.0k
Barbara van Zwieten‐Boot Netherlands	9	187 0.3×	49 0.2×	77 0.5×	22 0.2×	20 0.2×	11	502
Susan E. Libretto United Kingdom	10	83 0.1×	32 0.1×	46 0.3×	41 0.3×	64 0.5×	25	381
Salvatorica Manca Italy	15	167 0.3×	163 0.8×	49 0.3×	38 0.3×	39 0.3×	21	542
Dominic Heaney United Kingdom	18	452 0.7×	63 0.3×	401 2.6×	98 0.8×	16 0.1×	35	727
Kuo‐You Huang Taiwan	10	138 0.2×	49 0.2×	19 0.1×	18 0.1×	22 0.2×	23	369
Rebecca Hanson United States	10	355 0.6×	55 0.3×	290 1.9×	90 0.7×	6 0.0×	13	573

Countries citing papers authored by Rafael Muniz

Since Specialization

Citations

This map shows the geographic impact of Rafael Muniz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rafael Muniz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rafael Muniz more than expected).

Fields of papers citing papers by Rafael Muniz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rafael Muniz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rafael Muniz. The network helps show where Rafael Muniz may publish in the future.

Co-authorship network of co-authors of Rafael Muniz

This figure shows the co-authorship network connecting the top 25 collaborators of Rafael Muniz. A scholar is included among the top collaborators of Rafael Muniz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rafael Muniz. Rafael Muniz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Alten, Rieke, et al.. (2020). Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis. International Journal of Rheumatic Diseases. 23(11). 1514–1525. 10 indexed citations

Genovese, Mark C., et al.. (2020). Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies. RMD Open. 6(1). e000987–e000987. 18 indexed citations

Huizinga, T., Yoshifumi Torii, & Rafael Muniz. (2020). Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity. Rheumatology and Therapy. 8(1). 41–61. 36 indexed citations

Bush, Jim, et al.. (2019). A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects. BMC Pharmacology and Toxicology. 20(1). 87–87. 11 indexed citations

Alten, Rieke, et al.. (2019). P422 Immunogenicity of a proposed adalimumab biosimilar, FKB327, and the reference product in patients with rheumatoid arthritis. Journal of Crohn s and Colitis. 13(Supplement_1). S320–S320. 3 indexed citations

Blevins, Thomas, et al.. (2018). Efficacy and safety of MYL‐1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase III INSTRIDE 2 study. Diabetes Obesity and Metabolism. 21(1). 129–135. 18 indexed citations

Silva, Raul R., et al.. (2013). Extended-Release Dexmethylphenidate 30 mg/d Versus 20 mg/d. Clinical Neuropharmacology. 36(4). 117–121. 6 indexed citations

Brams, Matthew, et al.. (2012). A Randomized, Double-Blind Study of 30 Versus 20 mg Dexmethylphenidate Extended-Release in Children With Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychopharmacology. 32(5). 637–644. 11 indexed citations

Childress, Ann, Thomas Spencer, Frank A. López, et al.. (2009). Efficacy and Safety of Dexmethylphenidate Extended-Release Capsules Administered Once Daily to Children with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology. 19(4). 351–361. 27 indexed citations

10.

Tucker, James D., Willi Suter, Dayton M. Petibone, et al.. (2009). Cytogenetic assessment of methylphenidate treatment in pediatric patients treated for attention deficit hyperactivity disorder. Mutation Research/Genetic Toxicology and Environmental Mutagenesis. 677(1-2). 53–58. 18 indexed citations

11.

Muniz, Rafael, et al.. (2008). Efficacy and Safety of Extended-Release Dexmethylphenidate Compared with d,l -Methylphenidate and Placebo in the Treatment of Children with Attention-Deficit/Hyperactivity Disorder: A 12-Hour Laboratory Classroom Study. Journal of Child and Adolescent Psychopharmacology. 18(3). 248–256. 36 indexed citations

12.

Brams, Matthew, Rafael Muniz, Ann Childress, et al.. (2008). A Randomized, Double-Blind, Crossover Study of Once-Daily Dexmethylphenidate in Children with Attention-Deficit Hyperactivity Disorder. CNS Drugs. 22(8). 693–704. 37 indexed citations

13.

Silva, Raul R., Rafael Muniz, Linda Pestreich, et al.. (2008). Dexmethylphenidate ExtendeD-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder. Journal of the American Academy of Child & Adolescent Psychiatry. 47(2). 199–208. 24 indexed citations

14.

Markowitz, John S., C. Lindsay DeVane, Linda Pestreich, Kennerly S. Patrick, & Rafael Muniz. (2006). A Comprehensive In Vitro Screening of d-, l- , and dl-threo -Methylphenidate: An Exploratory Study. Journal of Child and Adolescent Psychopharmacology. 16(6). 687–698. 85 indexed citations

15.

Silva, Raul R., Rafael Muniz, Linda Pestreich, et al.. (2006). Efficacy and Duration of Effect of Extended-Release Dexmethylphenidate Versus Placebo in Schoolchildren With Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology. 16(3). 239–251. 39 indexed citations

16.

Greenhill, Laurence L., et al.. (2006). Efficacy and Safety of Dexmethylphenidate Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder. Journal of the American Academy of Child & Adolescent Psychiatry. 45(7). 817–823. 46 indexed citations

17.

Spencer, Thomas, Lenard A. Adler, James J. McGough, et al.. (2006). Efficacy and Safety of Dexmethylphenidate Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder. Biological Psychiatry. 61(12). 1380–1387. 119 indexed citations

18.

Silva, Raul, Rafael Muniz, Linda Pestreich, et al.. (2005). Efficacy of Two Long-Acting Methylphenidate Formulations in Children with Attention- Deficit/Hyperactivity Disorder in a Laboratory Classroom Setting. Journal of Child and Adolescent Psychopharmacology. 15(4). 637–654. 41 indexed citations

19.

Liu, Feng, Rafael Muniz, Haruka Minami, & Raul R. Silva. (2005). Review and Comparison of the Long Acting Methylphenidate Preparations. Psychiatric Quarterly. 76(3). 259–269. 11 indexed citations

20.

Markowitz, John S., Arthur B. Straughn, Kennerly S. Patrick, et al.. (2003). Pharmacokinetics of Methylphenidate After Oral Administration of Two Modified-Release Formulations in Healthy Adults. Clinical Pharmacokinetics. 42(4). 393–401. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact